A review analysis by Professor Melissa Schilling, a strategy and innovation expert at the New York University’s Stern School of Business, suggests a strong link between diabetes and Alzheimer’s disease. The study, “Unraveling Alzheimer’s: Making Sense of the Relationship between Diabetes and Alzheimer’s Disease,” was published in…
Face recognition difficulties in Alzheimer’s patients have typically been attributed to underlying episodic and semantic memory impairment. Dr. Sven Joubert, Ph.D., from the Centre de recherche de l’Institut universitaire de gériatrie de Montréal, and colleagues have found that more than causing memory problems, Alzheimer’s also impairs visual face perception, a…
Researchers at Université Laval in Canada demonstrated that aging mice in a model of Alzheimer’s disease (AD) were less able to regulate their body temperatures, and when exposed to a cold environment showed increased AD manifestations. These results suggest correction of thermoregulation might be a therapeutic avenue for Alzheimer’s. The study, “Impaired thermoregulation and…
Dublin, Ireland-based global pharmaceutical company Allergan and Heptares Therapeutics, a clinical-stage pharmaceutical company whose proprietary technologies have created new medicines with the potential to transform Alzheimer’s disease, have entered into a global research and development and commercialization partnership for the treatment of Alzheimer’s…
Oryzon Genomics recently announced the dosing of a first subject in its Phase 1 trial of oral LSD1-MAOB dual selective inhibitor ORY-2001, targeting memory loss and cognitive decline in Alzheimer’s disease. The single and multiple ascending dose study will evaluate the safety, tolerability, and pharmacokinetics of ORY-2001 in healthy subjects. The trial is randomized, double-blind,…
Two important Alzheimer’s research organizations, Researchers Against Alzheimer’s (RA2) and Us Against Alzheimer’s (UsA2), will host an Alzheimer’s Talks Teleconference on April 11 to discuss recently released findings of an analysis of late-stage drug candidates to treat the disease. Significant findings in the analysis, released in March, include: There are 17 drugs in late-stage…
Researchers have identified a group of agricultural chemicals — pesticides and fungicides — that constitute environmental risk factors for neurological and neurodegenerative diseases. A recent study found that a number of these chemicals produce gene expression changes in mouse neurons similar to those observed in people with autism, Alzheimer’s disease, and other conditions. The paper, “…
Before any signs of cognitive decline start showing, neuronal synaptic connections are lost in mice destined to develop Alzheimer’s. New research shows that microglia – brain immune cells – destroy synapses in a fashion resembling processes in the developing brain, suggesting that it might be possible to develop drugs targeting…
Researchers tested the effects of fingolimod, an approved treatment for multiple sclerosis shown to have anti-inflammatory properties, in a mouse model of Alzheimer’s disease (AD). The drug reduced the density of pathological plaques and decreased the number of pro-inflammatory cells in in vivo disease models, suggesting a potential therapeutic role for Alzheimer’s.
More than 15 million unpaid caregivers around the world are estimated to provide daily care to people living with Alzheimer’s disease, usually without much outside support and often at risk to their own health and wellbeing. A collaborative research team at Indiana University-Purdue University Indianapolis (IUPUI)…
Get regular updates to your inbox.